Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3777MR)

This product GTTS-WQ3777MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3777MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14479MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ2065MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ10335MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ1393MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ11572MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ9227MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ4791MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ7720MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW